Daily Cardiology Research Analysis
Three impactful cardiology studies stood out today: a designer cytokine (IC7Fc) robustly reduced hyperlipidemia and atherosclerosis in a humanized mouse model, a pooled patient-level analysis demonstrated favorable 5-year outcomes and durability of the Portico TAVR system, and a simple two-parameter ECG algorithm outperformed current ESC criteria for detecting infranodal conduction delay after TAVI-related LBBB.
Summary
Three impactful cardiology studies stood out today: a designer cytokine (IC7Fc) robustly reduced hyperlipidemia and atherosclerosis in a humanized mouse model, a pooled patient-level analysis demonstrated favorable 5-year outcomes and durability of the Portico TAVR system, and a simple two-parameter ECG algorithm outperformed current ESC criteria for detecting infranodal conduction delay after TAVI-related LBBB.
Research Themes
- Long-term durability and conduction risk management after TAVR
- Translational immuno-metabolic therapies targeting atherosclerosis
- Practical ECG-based risk stratification for post-TAVI conduction disease
Selected Articles
1. The designer cytokine IC7Fc attenuates atherosclerosis development by targeting hyperlipidemia in mice.
In a humanized lipoprotein mouse model, IC7Fc lowered triglycerides and total cholesterol by suppressing hepatic de novo lipogenesis, increasing bile acid synthesis, and downregulating apolipoprotein B. These lipid effects translated into markedly reduced atherosclerotic lesions and vascular inflammation compared with current antihyperlipidemic therapy.
Impact: This study identifies a mechanistically distinct cytokine-based therapy that addresses both hyperlipidemia and vascular inflammation, pointing to a potentially paradigm-shifting approach for atherosclerosis.
Clinical Implications: While preclinical, IC7Fc’s dual lipid-lowering and anti-inflammatory actions suggest a future therapy that may complement or outperform current lipid-lowering strategies, meriting early-phase clinical trials.
Key Findings
- IC7Fc significantly lowered plasma triglycerides and total cholesterol in APOE*3-Leiden.CETP mice.
- Mechanisms included inhibition of hepatic de novo lipogenesis, increased bile acid synthesis, and reduced apolipoprotein B synthesis leading to diminished VLDL cholesterol secretion.
- IC7Fc reduced atherosclerotic lesion burden and vascular inflammation compared with current antihyperlipidemic therapy.
Methodological Strengths
- Use of APOE*3-Leiden.CETP mice with humanized lipoprotein metabolism enhances translational relevance.
- Mechanistic depth spanning hepatic lipogenesis, bile acid synthesis, and apolipoprotein pathways.
Limitations
- Findings are limited to murine models; human efficacy and safety remain unknown.
- Long-term adverse effects and immunogenicity of a cytokine-fusion protein were not assessed.
Future Directions: Conduct phase 1/2 trials to evaluate safety, lipid effects, and vascular inflammation in humans; explore combination with statins/PCSK9 inhibitors and effects on plaque regression.
The chimeric cytokine IC7Fc conveys the metabolic signaling properties of the glycoprotein 130 receptor cytokines interleukin-6 and ciliary neurotrophic factor via membrane-bound signaling. IC7Fc was previously shown to slow the progression of type 2 diabetes mellitus, and here, we demonstrate its effect on atherosclerotic development. In APOE*3-Leiden.CETP mice, an atherosclerosis-prone model with a humanized lipoprotein metabolism, IC7Fc markedly lowered plasma triglyceride and total cholesterol levels. This was mechanistically explained by an inhibition of de novo lipogenesis in the liver, increased synthesis of bile acids from cholesterol, and down-regulated apolipoprotein B synthesis, which resulted in decreased cholesterol secretion in very low-density lipoprotein particles. As a consequence, IC7Fc treatment considerably reduced atherosclerotic lesion formation and vascular inflammation compared with current antihyperlipidemic therapy. In conclusion, IC7Fc is a promising pharmacological treatment for cardiometabolic diseases targeting hyperlipidemia and inflammation.
2. Five-Year Clinical Outcomes and Durability of a Self-Expanding Transcatheter Heart Valve With Intra-Annular Leaflets.
In 1464 high/extreme surgical-risk TAVR patients pooled across harmonized studies with core lab and adjudication, 5-year all-cause mortality was 49.4% and stroke 12.3%. Hemodynamics were sustained (mean gradient ~6.2 mmHg; EOA ~1.83), bioprosthetic valve failure was low, and no severe hemodynamic structural valve deterioration was observed at 5 years.
Impact: Provides robust, multi-study 5-year durability and performance data for a self-expanding intra-annular TAVR valve, informing device choice and long-term management.
Clinical Implications: Supports the Portico valve as a durable option with sustained low gradients and low failure rates at 5 years, aiding shared decision-making in high-risk TAVR candidates.
Key Findings
- Pooled 1464 high/extreme-risk TAVR patients across harmonized studies with core lab and blinded adjudication.
- At 5 years: all-cause mortality 49.4%, stroke 12.3%, mean transvalvular gradient 6.2 mmHg, effective orifice area ~1.83.
- Low bioprosthetic valve failure with no severe hemodynamic structural valve deterioration at 5 years.
Methodological Strengths
- Patient-level pooled analysis across harmonized prospective studies with centralized core lab and independent adjudication.
- Standardized definitions (VARC-2; durability aligned with VARC-3/EAPCI/ESC/EACTS).
Limitations
- Nonrandomized pooling of different study designs; potential residual confounding.
- Generalizability to younger or lower-risk populations is uncertain.
Future Directions: Head-to-head long-term durability comparisons across TAVR platforms, assessment of leaflet thickening/thrombosis, and evaluation in younger/lower-risk cohorts.
BACKGROUND: There is a paucity of data regarding the longer-term durability of transcatheter heart valves. This analysis aimed to describe the 5-year clinical outcomes and valve durability for patients treated with the Portico transcatheter heart valves across 3 studies harmonized in their prospective enrollment, inclusion/exclusion criteria, centralized independent core laboratory echocardiographic analysis, and independent clinical events committee adjudication. METHODS: Patient-level data from the PORTICO IDE randomized controlled trial, the PORTICO I postmarket study, and the PORTICO continued access protocol were pooled using a random-effects meta-analysis model. All 3 studies collected follow-up data at discharge, 30 days, and annually through 5 years. Adverse events and pooled echocardiographic data were assessed using Valve Academic Research Consortium-2 definitions. Durability definitions were adapted from Valve Academic Research Consortium-3 and European Association of Percutaneous Cardiovascular Interventions/European Society of Cardiology/European Association for Cardio-Thoracic Surgery consensus guidelines. RESULTS: A total of 1464 patients with severe symptomatic aortic stenosis and high or extreme surgical risk were included. Median age was 83 years, 61.7% were women, and the median Society of Thoracic Surgeons score was 4.9%. At 5 years, all-cause mortality and stroke rates were 49.4% and 12.3%, respectively. Transvalvular gradient and effective orifice area at 5 years were 6.2 mm Hg and 1.83 cm CONCLUSIONS: The use of the Portico transcatheter heart valve system in patients at high or extreme surgical risk demonstrated favorable clinical outcomes and hemodynamic performance with low transvalvular gradients and greater than mild paravalvular leak. Furthermore, bioprosthetic valve failure rates were low with no incidence of severe hemodynamic structural valve deterioration at 5 years, irrespective of annular size. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02000115 and NCT01802788.
3. Risk Stratification in Left Bundle Branch Block After Transcatheter Aortic Valve Implantation: A Multicenter ECG Algorithm Study.
In 769 post-TAVI patients with LBBB undergoing EP testing, a simple ECG rule using only post-TAVI PR and QRS cutoffs (PR <190 ms and QRS <160 ms to rule-out; PR ≥190 ms and QRS ≥160 ms to rule-in) outperformed ESC criteria, with sensitivity 88%/NPV 92% for rule-out and specificity 85%/PPV 41% for rule-in.
Impact: The algorithm offers an immediately implementable tool to guide pacemaker decisions by accurately identifying infranodal delay after TAVI-related LBBB.
Clinical Implications: Using PR and QRS thresholds can safely rule out infranodal delay (high NPV) and improve rule-in performance compared with ESC criteria, potentially reducing unnecessary pacing while identifying high-risk patients.
Key Findings
- Multicenter prospective cohort of 769 post-TAVI LBBB patients with EP testing as reference standard.
- Simple ECG algorithm (post-TAVI PR and QRS only) achieved 88% sensitivity/92% NPV for rule-out and 85% specificity/41% PPV for rule-in of infranodal delay.
- ESC ECG criteria underperformed (sensitivity 72%, specificity 53%, PPV 28%, NPV 88%) compared with the new algorithm.
Methodological Strengths
- Prospective, multicenter design with EP testing gold standard.
- Simple, generalizable ECG cutoffs enabling bedside implementation.
Limitations
- Observational design without external validation cohort; PPV remains modest (41%).
- Algorithm performance on long-term outcomes and across device types not assessed.
Future Directions: External validation and integration into clinical pathways; evaluate impact on pacing rates, outcomes, and cost-effectiveness.
BACKGROUND: Managing left bundle branch block (LBBB) after transcatheter aortic valve implantation (TAVI) remains challenging. OBJECTIVES: The aim of this study was to develop a novel, simplified electrocardiogram (ECG) algorithm for predicting infranodal conduction delay in LBBB (both new onset as well as preexisting) patients after TAVI and to compare its performance vs current European Society of Cardiology (ESC) ECG criteria. METHODS: A multicenter analysis of prospectively enrolled patients undergoing electrophysiology testing for preexisting or new-onset LBBB after TAVI was conducted. The novel algorithm was developed by analyzing various combinations of the PR interval, QRS duration pre-TAVI and post-TAVI, and changes in these parameters to identify patients with infranodal conduction delay (defined as a His-ventricular interval ≥70 milliseconds). RESULTS: A total of 769 patients with LBBB (12% preexisting) after TAVI underwent risk stratification using electrophysiology testing at 7 institutions (mean age 81 ± 7 years; 57% female; 21% His-ventricular ≥70 milliseconds). A novel algorithm using solely a PR interval of 190 milliseconds and a QRS interval of 160 milliseconds revealed a sensitivity of 88% and an negative predictive value of 92% for the rule-out of infranodal conduction delay (PR interval post-TAVI <190 milliseconds AND QRS duration post-TAVI <160 milliseconds) and a specificity and positive predictive value of 85% and 41%, respectively, for the rule-in of infranodal conduction delay (PR interval post-TAVI ≥190 milliseconds AND QRS duration post-TAVI ≥160 milliseconds). By comparison, the ESC ECG criteria showed a sensitivity of 72%, a negative predictive value of 88%, specificity of 53%, and a positive predictive value of 28%. CONCLUSIONS: The novel, simplified ECG algorithm showed a superior performance for the rule-out and rule-in of infranodal conduction delay compared with current ESC ECG criteria.